International Conference on Cold Fusion

SHINE Technologies Will Participate at 11th International Conference on Isotopes

Retrieved on: 
Monday, July 24, 2023

JANESVILLE, Wis., July 24, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced that Todd Asmuth, president and chief strategy officer of SHINE, will give an invited panel presentation during the 11th International Conference on Isotopes from July 23-27 in Saskatoon, Saskatchewan, Canada.

Key Points: 
  • JANESVILLE, Wis., July 24, 2023 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company, today announced that Todd Asmuth, president and chief strategy officer of SHINE, will give an invited panel presentation during the 11th International Conference on Isotopes from July 23-27 in Saskatoon, Saskatchewan, Canada.
  • On Thursday, July 27, Asmuth will present "Demand and Supply of Medical Isotopes" alongside other industry leaders and members of parliament.
  • The International Conference on Isotopes , typically held every other year since 1995, is organized by the World Council on Isotopes and a participating organization to highlight the importance of nuclear science, medicine and technology in advancing human health and the protection of the environment.
  • In its second phase, SHINE is creating critical medical isotopes used to diagnose and treat life-threatening diseases in patients across the globe.

Data Presented at the 2023 American Academy of Dental Sleep Medicine and the American Thoracic Society Meetings Further Validate ProSomnus Precision Oral Appliance Therapy for the Treatment of Obstructive Sleep Apnea

Retrieved on: 
Tuesday, May 30, 2023

100% of patients adhered to OAT, while 83% of patients adhered to CPAP.

Key Points: 
  • 100% of patients adhered to OAT, while 83% of patients adhered to CPAP.
  • Liners: 98.5% of AERs involved lab-formed OATs with and without liners, while just 1.5% of AERs involved precision-engineered liner-less devices.
  • “Precision oral appliance therapy consists of intraoral medical devices that precisely track to the healthcare provider’s treatment plan and the patient’s anatomy,” said Len Liptak, Chief Executive Officer of ProSomnus.
  • “This data further validates that our non-invasive, patient-preferred, precision oral appliance therapy is associated with excellent outcomes for patients with OSA.”

Axalbion Presented Promising Phase 2 Clinical Data in Chronic Cough with AX-8, a Novel TRPM8 Agonist, in an Oral Presentation at the American Thoracic Society (ATS) 2023 International Conference

Retrieved on: 
Monday, May 22, 2023

( ClinicalTrials.gov NCT04866563 ; EudraCT Number 2021-000844-23).

Key Points: 
  • ( ClinicalTrials.gov NCT04866563 ; EudraCT Number 2021-000844-23).
  • “Refractory chronic cough is a burdensome condition that significantly impacts a patient’s quality of life, leading to urinary incontinence, social stigma, sleep disturbances, anxiety, depression and social isolation.
  • AX-8 shows promising results in this proof-of-concept study with a robust reduction in cough frequency in patients experiencing the greatest throat discomfort.
  • “We believe that AX-8 acts as a counterirritant that activates TRPM8 channels in throat sensory fibers.

Upstream Bio to Present New Clinical Data from Phase 1 Study of UPB-101 at the American Thoracic Society (ATS) International Conference

Retrieved on: 
Friday, May 12, 2023

Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced an upcoming poster presentation featuring new clinical data from its Phase 1 clinical study of UPB-101 at the American Thoracic Society (ATS) International Conference, happening May 19-24 in Washington, DC.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced an upcoming poster presentation featuring new clinical data from its Phase 1 clinical study of UPB-101 at the American Thoracic Society (ATS) International Conference, happening May 19-24 in Washington, DC.
  • The poster, co-authored by Aaron Deykin,1 Chaim M. Brickman,1 Peter Lloyd,2 Oren M. Becker,1 will be presented on Monday, May 22, 2023, at 11:30am ET.
  • An e-poster will also be made available to conference attendees during the event.

PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022

Retrieved on: 
Monday, May 16, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of additional data for PureTechs LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of additional data for PureTechs LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.
  • Key outcomes of this study that are supportive of the observed improved tolerability of LYT-100 were reported in January 2022.
  • View the full release here: https://www.businesswire.com/news/home/20220516005130/en/
    PureTech today announced the presentation of additional data for PureTech's LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference.
  • PureTech also expects to initiate registration-enabling studies of LYT-100 in patients with IPF in the first half of 2022.

NovoEd to Sponsor ATD International Conference & Expo 2021 in Salt Lake City

Retrieved on: 
Tuesday, August 24, 2021

WHAT:NovoEd, the leading social and collaborative learningplatform for deep capability building, is proud to announce its sponsorship of the ATD 2021 International Conference & Exposition , a hybrid event set for in-person attendance at the Salt Palace Convention Center in Salt Lake City (components of the event will also be available online).

Key Points: 
  • WHAT:NovoEd, the leading social and collaborative learningplatform for deep capability building, is proud to announce its sponsorship of the ATD 2021 International Conference & Exposition , a hybrid event set for in-person attendance at the Salt Palace Convention Center in Salt Lake City (components of the event will also be available online).
  • There will also be a featured Floor Demo, "Transforming Onboarding & Reskilling for a Hybrid Workforce" on Monday, Aug. 30 from 10:15-10:45 a.m. MDT.
  • NovoEd's Solutions Consultant Juan Morn will demonstrate how the right technology is foundational for connecting powerful learning to business outcomes.
  • NovoEd will host a VIP cocktail mixer during the conference from 6-8:30 p.m. MDT on Monday, Aug. 30.